Modivcare Reports First Quarter 2022 Financial Results
Modivcare Inc. (Nasdaq: MODV) reported a 26.6% revenue increase to $574.5 million for Q1 2022, up from $453.6 million in Q1 2021. However, net income fell to $0.3 million or $0.02 per diluted share, a significant drop from $18.8 million or $1.31 per share a year prior. Adjusted EBITDA of $50.3 million represented 8.8% of revenue, slightly higher than the previous year, but operating income decreased to $14.9 million, reflecting 2.6% of revenue. The company noted the impact of acquisitions and an increase in non-emergency medical transportation revenue.
- Revenue grew by 26.6% year-over-year to $574.5 million.
- Incremental revenue of $44.4 million from Care Finders acquisition.
- Incremental revenue of $13.9 million from VRI acquisition.
- Adjusted EBITDA increased to $50.3 million due to acquisitions.
- Net income decreased significantly to $0.3 million compared to $18.8 million in Q1 2021.
- Operating income dropped to $14.9 million, down from $28.8 million, reflecting declining profitability.
- Adjusted EPS fell to $1.57 from $2.06 in Q1 2021.
First Quarter 2022 Highlights:
-
Revenue of
, a$574.5 million 26.6% increase as compared to in Q1 2021$453.6 million
-
Net income of
or$0.3 million per diluted common share$0.02
-
Adjusted EBITDA of
, Adjusted Net Income of$50.3 million and Adjusted EPS of$22.2 million $1.57
-
Net cash provided by operating activities during the quarter of
$69.1 million
-
Cash and cash equivalents of
as of$194.1 million March 31, 2022 , with principal amount of debt outstanding related to the Senior Unsecured Notes due 2025 and 2029$1,000.0 million
-
Undrawn
revolving credit facility as of$325.0 million March 31, 2022
“This quarter, we advanced our strategy to improve outcomes and better serve the health needs of patients through our supportive care platform,” said
First Quarter 2022 Results
For the first quarter of 2022, the Company reported revenue of
Operating income was
Adjusted EBITDA was
Adjusted Net Income in the first quarter of 2022 was
Comparable adjusted EBITDA and Adjusted Net Income for Q1 2021 was recast to show the impact of cash settled equity, which the Company is now excluding for the purpose of these calculations.
The year-over-year increase in revenue was primarily due to incremental revenue of
Adjusted EBITDA increased in the first quarter of 2022 due to incremental contribution from Care Finders and VRI. This was partially offset by higher corporate general and administrative cost as the Company continued to make investments in its employees and technology.
Organizational Consolidation and Change in Segments
Effective
Investor Presentation and Conference Call
US toll-free: 1 (877) 423 9820
International: 1 (201) 493 6749
You may also access the conference call via webcast at investors.modivcare.com, where the call also will be archived.
About
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our long-lived assets; any failure to maintain or to develop further reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; any failure to obtain the consent of the
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent filings most recently filed with the
--financial tables to follow--
|
||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||
(in thousands, except share and per share data) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
|
||||
Service revenue, net |
|
$ |
574,475 |
|
|
$ |
453,610 |
|
Grant income |
|
|
468 |
|
|
|
2,648 |
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
||||
Service expense |
|
|
459,315 |
|
|
|
360,333 |
|
General and administrative expense |
|
|
76,808 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Total operating expenses |
|
|
560,069 |
|
|
|
427,497 |
|
|
|
|
|
|
||||
Operating income |
|
|
14,874 |
|
|
|
28,761 |
|
|
|
|
|
|
||||
Other expenses: |
|
|
|
|
||||
Interest expense, net |
|
|
15,400 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
|
(526 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
|
(361 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
|
(483 |
) |
|
|
(3,241 |
) |
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
|
||||
Earnings per common share: |
|
|
|
|
||||
Basic |
|
$ |
0.02 |
|
|
$ |
1.33 |
|
Diluted |
|
$ |
0.02 |
|
|
$ |
1.31 |
|
|
|
|
|
|
||||
Weighted-average number of common shares outstanding: |
|
|
|
|
||||
Basic |
|
|
14,023,585 |
|
|
|
14,158,666 |
|
Diluted |
|
|
14,143,548 |
|
|
|
14,362,226 |
|
|
||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||
(in thousands) |
||||||
|
|
|
|
|
||
|
|
|
|
|
||
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
194,063 |
|
$ |
133,139 |
Accounts receivable, net |
|
|
262,589 |
|
|
233,121 |
Other current assets (1) |
|
|
52,405 |
|
|
43,574 |
Total current assets |
|
|
509,057 |
|
|
409,834 |
Property and equipment, net |
|
|
57,676 |
|
|
53,549 |
|
|
|
1,395,511 |
|
|
1,415,000 |
Equity investment |
|
|
83,333 |
|
|
83,069 |
Operating lease right-of-use assets |
|
|
42,181 |
|
|
43,750 |
Other long-term assets |
|
|
25,226 |
|
|
22,223 |
Total assets |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
|
|
|
|
|
||
Liabilities and stockholders' equity |
||||||
Current liabilities: |
|
|
|
|
||
Accounts payable |
|
$ |
38,050 |
|
$ |
8,690 |
Accrued contract payables |
|
|
314,126 |
|
|
281,586 |
Accrued expenses and other current liabilities |
|
|
138,071 |
|
|
119,563 |
Accrued transportation costs |
|
|
107,190 |
|
|
103,294 |
Current portion of operating lease liabilities |
|
|
9,858 |
|
|
9,873 |
Deferred revenue |
|
|
5,648 |
|
|
4,228 |
Total current liabilities |
|
|
612,943 |
|
|
527,234 |
Long-term debt, net of deferred financing costs |
|
|
976,233 |
|
|
975,225 |
Operating lease liabilities, less current portion |
|
|
34,092 |
|
|
34,524 |
Long-term contracts payables |
|
|
1,893 |
|
|
— |
Other long-term liabilities (2) |
|
|
111,623 |
|
|
117,175 |
Total liabilities |
|
|
1,736,784 |
|
|
1,654,158 |
|
|
|
|
|
||
Stockholders' equity |
|
|
|
|
||
Stockholders' equity |
|
|
376,200 |
|
|
373,267 |
Total liabilities and stockholders' equity |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
(1) |
Includes other receivables, prepaid expenses and other current assets and short-term restricted cash. |
|
(2) |
Includes other long-term liabilities and deferred tax liabilities. |
|
||||||||
Unaudited Condensed Consolidated Statements of Cash Flows |
||||||||
(in thousands) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Stock-based compensation |
|
|
2,049 |
|
|
|
1,187 |
|
Equity in net income of investee |
|
|
(483 |
) |
|
|
(4,503 |
) |
Deferred income taxes |
|
|
(6,587 |
) |
|
|
(616 |
) |
Reduction of right-of-use asset |
|
|
2,884 |
|
|
|
2,745 |
|
Other non-cash items (1) |
|
|
(777 |
) |
|
|
608 |
|
Changes in working capital (2) |
|
|
47,720 |
|
|
|
104,064 |
|
Net cash provided by operating activities |
|
|
69,070 |
|
|
|
134,564 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Purchase of property and equipment |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
Net cash used in investing activities |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Repurchase of common stock, for treasury |
|
|
— |
|
|
|
(14,450 |
) |
Proceeds from common stock issued pursuant to stock option exercise |
|
|
1,138 |
|
|
|
2,286 |
|
Restricted stock surrendered for employee tax payment |
|
|
(572 |
) |
|
|
(721 |
) |
Other financing activities |
|
|
— |
|
|
|
(40 |
) |
Net cash provided by (used in) financing activities |
|
|
566 |
|
|
|
(12,925 |
) |
|
|
|
|
|
||||
Net change in cash, cash equivalents and restricted cash |
|
|
61,052 |
|
|
|
116,251 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
133,422 |
|
|
|
183,356 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
194,474 |
|
|
$ |
299,607 |
|
(1) |
Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount. |
|
(2)
|
Includes accounts receivable and other receivables, prepaid expenses and other current assets, self-funded insurance programs, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs, deferred revenue and other long-term liabilities. |
|
|
|||||||||||||||||
|
Three months ended |
||||||||||||||||
|
NEMT |
|
Personal Care |
|
RPM |
|
Corporate (3) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
400,920 |
|
$ |
159,698 |
|
$ |
13,857 |
|
|
$ |
— |
|
|
$ |
574,475 |
|
Grant income |
|
— |
|
|
468 |
|
|
— |
|
|
|
— |
|
|
|
468 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||
Service expense |
|
332,096 |
|
|
122,232 |
|
|
4,987 |
|
|
|
— |
|
|
|
459,315 |
|
General and administrative expense |
|
37,333 |
|
|
23,133 |
|
|
4,962 |
|
|
|
11,380 |
|
|
|
76,808 |
|
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
Total operating expenses |
|
376,534 |
|
|
157,870 |
|
|
14,077 |
|
|
|
11,588 |
|
|
|
560,069 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(11,588 |
) |
|
|
14,874 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Income (loss) before income taxes and equity method investment |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(26,988 |
) |
|
|
(526 |
) |
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
Net Income (loss) |
|
17,746 |
|
|
1,656 |
|
|
(162 |
) |
|
|
(18,922 |
) |
|
|
318 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
EBITDA |
|
31,426 |
|
|
14,801 |
|
|
3,908 |
|
|
|
(10,832 |
) |
|
|
39,303 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
5,604 |
|
|
181 |
|
|
24 |
|
|
|
31 |
|
|
|
5,840 |
|
Transaction costs (2) |
|
— |
|
|
1,273 |
|
|
647 |
|
|
|
1,791 |
|
|
|
3,711 |
|
Cash settled equity |
|
— |
|
|
— |
|
|
— |
|
|
|
(13 |
) |
|
|
(13 |
) |
Stock-based compensation |
|
— |
|
|
17 |
|
|
29 |
|
|
|
1,420 |
|
|
|
1,466 |
|
COVID-19 related costs, net of grant income |
|
122 |
|
|
349 |
|
|
— |
|
|
|
— |
|
|
|
471 |
|
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
37,217 |
|
$ |
16,621 |
|
$ |
4,608 |
|
|
$ |
(8,151 |
) |
|
$ |
50,295 |
|
(1) | Restructuring and related charges include professional services costs and severance and recruiting costs. |
|
(2) | Transaction costs include SOX integration efforts at recently acquired subsidiaries and acquisition costs. |
|
(3) |
Effective |
|
|
|||||||||||||||
|
Three months ended |
||||||||||||||
|
NEMT |
|
Personal Care |
|
Corporate (4) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
343,416 |
|
|
$ |
110,194 |
|
|
$ |
— |
|
|
$ |
453,610 |
|
Grant income |
|
— |
|
|
|
2,648 |
|
|
|
— |
|
|
|
2,648 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Service expense |
|
272,416 |
|
|
|
87,917 |
|
|
|
— |
|
|
|
360,333 |
|
General and administrative expense |
|
27,987 |
|
|
|
15,029 |
|
|
|
11,909 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
Total operating expenses |
|
307,715 |
|
|
|
107,873 |
|
|
|
11,909 |
|
|
|
427,497 |
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
35,701 |
|
|
|
4,969 |
|
|
|
(11,909 |
) |
|
|
28,761 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
35,701 |
|
|
|
4,969 |
|
|
|
(20,332 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
Net Income (loss) |
|
26,297 |
|
|
|
3,531 |
|
|
|
(10,988 |
) |
|
|
18,840 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
EBITDA |
|
43,013 |
|
|
|
9,896 |
|
|
|
(8,668 |
) |
|
|
44,241 |
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
3,494 |
|
|
|
— |
|
|
|
151 |
|
|
|
3,645 |
|
Transaction costs (2) |
|
(37 |
) |
|
|
1,045 |
|
|
|
2,670 |
|
|
|
3,678 |
|
Cash settled equity (3) |
|
— |
|
|
|
— |
|
|
|
2,093 |
|
|
|
2,093 |
|
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
1,131 |
|
|
|
1,131 |
|
COVID-19 related costs, net of grant income |
|
339 |
|
|
|
(1,852 |
) |
|
|
— |
|
|
|
(1,513 |
) |
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
46,809 |
|
|
$ |
9,089 |
|
|
$ |
(5,864 |
) |
|
$ |
50,034 |
|
(1) |
Restructuring and related charges include professional services costs of |
|
(2) |
Transaction costs include Circulation management incentive plan costs and acquisition costs related to |
|
(3) | Adjusted EBITDA for Q1 2021 was recast to show the impact of cash settled equity, which the Company is now including for the purpose of this calculation. |
|
(4) |
Effective |
|
|
|||||||
|
Three months ended |
||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
||||
Net income |
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
||||
Restructuring and related charges(1) |
|
5,840 |
|
|
|
3,645 |
|
Transaction costs(2) |
|
3,711 |
|
|
|
3,678 |
|
Cash settled equity(3) |
|
(13 |
) |
|
|
2,093 |
|
Stock-based compensation |
|
1,466 |
|
|
|
1,131 |
|
Equity in net income of investee, net of tax |
|
(483 |
) |
|
|
(3,241 |
) |
Intangible amortization expense |
|
19,490 |
|
|
|
9,502 |
|
COVID-19 related costs, net of grant income |
|
471 |
|
|
|
(1,513 |
) |
Tax effected impact of adjustments |
|
(8,629 |
) |
|
|
(4,536 |
) |
|
|
|
|
||||
Adjusted Net Income |
$ |
22,171 |
|
|
$ |
29,599 |
|
|
|
|
|
||||
Adjusted EPS |
$ |
1.57 |
|
|
$ |
2.06 |
|
|
|
|
|
||||
Diluted weighted-average number of common shares outstanding |
|
14,143,548 |
|
|
|
14,362,226 |
|
(1) | Restructuring and related charges include severance, organizational consolidation costs and professional fees. |
|
(2) | Transaction costs include certain transaction-related expenses and SOX integration efforts. |
|
(3) | Adjusted net income for Q1 2021 was recast to show the impact of cash-settled equity, which the Company is now including for the purpose of this calculation. |
|
|
||||||||||
|
Three months ended |
|
|
|||||||
|
|
|
|
|
% Change |
|||||
|
|
|
|
|
|
|||||
NEMT Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
400,920 |
|
|
$ |
343,416 |
|
|
16.7 |
% |
Service expense; purchased services |
|
277,947 |
|
|
|
223,294 |
|
|
24.5 |
% |
Service expense; payroll, and other |
|
54,149 |
|
|
|
49,122 |
|
|
10.2 |
% |
Gross profit |
$ |
68,824 |
|
|
$ |
71,000 |
|
|
(3.1 |
) % |
Gross margin |
|
17.2 |
% |
|
|
20.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
37,333 |
|
|
$ |
27,987 |
|
|
33.4 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
5,604 |
|
|
|
3,494 |
|
|
60.4 |
% |
Transaction costs |
|
— |
|
|
|
(37 |
) |
|
(100.0 |
) % |
Adjusted G&A expense |
$ |
31,729 |
|
|
$ |
24,530 |
|
|
29.3 |
% |
Adjusted G&A expense % of revenue |
|
7.9 |
% |
|
|
7.1 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
17,746 |
|
|
$ |
26,297 |
|
|
(32.5 |
) % |
Net income margin |
|
4.4 |
% |
|
|
7.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
37,217 |
|
|
$ |
46,809 |
|
|
(20.5 |
) % |
Adjusted EBITDA margin |
|
9.3 |
% |
|
|
13.6 |
% |
|
|
|
|
||||||||||
|
Three months ended |
|
|
|||||||
|
|
|
|
|
% Change |
|||||
|
|
|
|
|
|
|||||
Personal Care Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
159,698 |
|
|
$ |
110,194 |
|
|
44.9 |
% |
Service expense |
|
122,232 |
|
|
|
87,917 |
|
|
39.0 |
% |
Gross profit |
$ |
37,466 |
|
|
$ |
22,277 |
|
|
68.2 |
% |
Gross Margin |
|
23.5 |
% |
|
|
20.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
23,133 |
|
|
$ |
15,029 |
|
|
53.9 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
181 |
|
|
|
— |
|
|
NA |
|
Transaction costs |
|
1,273 |
|
|
|
1,045 |
|
|
21.8 |
% |
Stock-based compensation |
|
17 |
|
|
|
— |
|
|
NA |
|
Adjusted G&A expense |
$ |
21,662 |
|
|
$ |
13,984 |
|
|
54.9 |
% |
Adjusted G&A expense % of revenue |
|
13.6 |
% |
|
|
12.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
1,656 |
|
|
$ |
3,531 |
|
|
(53.1 |
) % |
Net income margin |
|
1.0 |
% |
|
|
3.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
16,621 |
|
|
$ |
9,089 |
|
|
82.9 |
% |
Adjusted EBITDA margin |
|
10.4 |
% |
|
|
8.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
RPM Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
13,857 |
|
|
|
|
|
|||
Service expense |
|
4,987 |
|
|
|
|
|
|||
Gross profit |
$ |
8,870 |
|
|
|
|
|
|||
Gross Margin |
|
64.0 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
G&A expense |
$ |
4,962 |
|
|
|
|
|
|||
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
24 |
|
|
|
|
|
|||
Transaction costs |
|
647 |
|
|
|
|
|
|||
Stock-based compensation |
|
29 |
|
|
|
|
|
|||
Adjusted G&A expense |
$ |
4,262 |
|
|
|
|
|
|||
Adjusted G&A expense % of revenue |
|
30.8 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Net loss |
$ |
(162 |
) |
|
|
|
|
|||
Net loss margin |
|
(1.2 |
) % |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
4,608 |
|
|
|
|
|
|||
Adjusted EBITDA margin |
|
33.3 |
% |
|
|
|
|
|||
|
||||||||||
|
Three months ended |
|
|
|||||||
|
|
|
|
|
% Change |
|||||
|
|
|
|
|
|
|||||
Corporate Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
G&A expense |
$ |
11,380 |
|
|
$ |
11,909 |
|
|
(4.4 |
) % |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
31 |
|
|
|
151 |
|
|
(79.5 |
) % |
Transaction costs |
|
1,791 |
|
|
|
2,670 |
|
|
(32.9 |
) % |
Cash settled equity |
|
(13 |
) |
|
|
2,093 |
|
|
(100.6 |
) % |
Stock-based compensation |
|
1,420 |
|
|
|
1,131 |
|
|
25.6 |
% |
Adjusted G&A expense |
$ |
8,151 |
|
|
$ |
5,864 |
|
|
39.0 |
% |
Adjusted G&A expense % of consolidated revenue |
|
1.4 |
% |
|
|
1.3 |
% |
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005303/en/
Investor Relations
Head of Investor Relations
(303) 728-7012
Kevin.ellich@modivcare.com
Source:
FAQ
What were Modivcare's Q1 2022 earnings results?
How did Modivcare's revenue in Q1 2022 compare to Q1 2021?